Share on LinkedInShare on LinkedIn

ARTICLE · 14 OCTOBER 2016

IPO's Patent To Gilead's Sofobuvir (Sovaldi) Challenged At Delhi High Court

A Writ Petition has been filed before the Delhi High Court, challenging the grant of patent for Gilead's megahit anti Hepatitis-C virus drug, sofobuvir which is known commercially everywhere as "Sovaldi".

IndiaIntellectual Property
Kavita Shah
Kavita Shah

A Writ Petition has been filed before the Delhi High Court, challenging the grant of patent for Gilead's megahit anti Hepatitis-C virus (HCV) drug, sofobuvir which is known commercially everywhere as "Sovaldi". The company charges a super hike price of $1,000 per pill in the USA. Though the price of the treatment in India is not expected to be very high due to local competition, with the generic version priced at a around $13.71 per pill in India, where domestic drugmakers may have planned to export the key raw material or others planning to launch the drug in the country are bound to be hit, argued by whom have decided to take the patent office to court.

The petition has been jointly filed by the non-for-profit group based in United States, Initiative for Medicines, Access & Knowledge (I-MAK) and the human rights group, Delhi Network of Positive People (DNP+). The challenge contends that the Indian Patent Office's judgment is contrary to public interest, and that it

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from